Newsbenzinga
Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…